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1. Introduction
In many regions, local laws and regulations permit the use of
cannabis for medicinal purposes in a manner that circumvents
well-established procedures for assessing the efficacy, safety,
manufacturing, and marketing of medicines. Moreover, the
availability of recreational cannabis effectively allows bypassing
of the regulatory protections placed on the use of medicinal
cannabis products.
Cannabis has been used by humans for millennia, including for
pain relief, historically described as a substance (pharmakon, in
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Greek) that can be a remedy as well as a poison.54,72,81 Currently,
cannabis is also the most commonly used illicit drug globally,6,22
with over 200 million users.40 The use of cannabis among
adolescents and young adults in the past decade has increased,
with 11% of Americans aged 18 years or older, and 22% of
Canadians aged 16 years or older reporting cannabis use in the
past month, with 7% to 11% reporting daily or almost daily use.33
In England and Wales, where recreational use is not legalized, an
estimated 2.1 million people use cannabis, mostly obtaining it
from illegal sources.48 Although currently available data from
randomized controlled trials neither support nor refute the safety
and efficacy of cannabis, cannabinoids, or cannabis-based
medicines (CBM) for managing pain,28 it is clear that the use of
cannabis is expanding globally.
The use of cannabis without proper regulation of manufacturing and supply, together with ready access to unregulated, and
often illicit, markets of high-concentration products, can result in
major societal risks and harms. This topical review, as a part of the
work by International Association for the Study of Pain (IASP)
Presidential Taskforce on Cannabis and Cannabinoid Analgesia,
will focus on societal issues and policy implications related to use
of cannabinoids, cannabis, and CBM for pain management.

2. Regulation of cannabis cultivation
Growing cannabis plants, and subsequent extraction or formulation processes, presents legal complexities and challenges due
to a wide jurisdictional variability in laws and operational
approaches. For example, within the European Union, growing
cannabis plants that contain ,0.2% D9-tetrahydrocannabinol
(THC) (referred to as hemp) is legal, but there have been arrests in
some European Union countries for the sale of hemp-based
products if they contain any detectable amount of D9-THC.42
Being a plant, the growth and precise composition of cannabis,
including its phytocannabinoid content, is subject to a wide
variety of influences. These include, but are not limited to, plant
genetics, lighting levels, temperature, humidity and water
availability, soil composition, and nutrient availability. To best
control these parameters, particularly for cannabis intended for
medicinal use, indoor growing is typically favored over outdoor
growing.
Over the past 4 decades, cannabis potency, indicated by the
THC content in seized samples, has increased significantly
worldwide,12,26,38,39 and has doubled in Europe over the past
decade,30 posing risks in the context of its unregulated use.
Regulatory issues also exist with cannabidiol (CBD), a
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phytocannabinoid used as an individual compound, infused in
food products, or in combination with THC. The U.S. Food and
Drug Administration (FDA) and other regulatory bodies around the
world have found that more than 90% of CBD products contained
substantially less CBD than labeled, and some contained
substantial amounts of THC.8 In addition to variability in
phytocannabinoid composition, the presence of harmful contaminants, eg, pesticides, herbicides, molds, bacteria, metals,
and solvents, are particularly concerning when used for medical
purposes by vulnerable populations such as children, patients
with malignancies or HIV, or those treated with immunosuppressants.49,64,67 However, major regulatory bodies such as the U.S.
Environmental Protection Agency have not provided guidance on
which cannabis-related exposures can be considered safe, or
how to regulate contaminants. In the absence of universally
accepted regulations, some countries and states have determined their own requirements, resulting in an incoherent
global regulatory landscape of cannabis cultivation, which is far
below standards compatible with pharmaceutical manufacturing
of medicines for human use. The physical infrastructure and
energy consumption, artificial light, irrigation, and temperature
control associated with indoor cannabis growing, especially in
areas with scarce water resources, should also be considered in
the context of environmental sustainability and carbon footprint of
cannabis cultivation.3,47 The expansion of outdoor cultivation for
economic benefit (eg, in developing countries, to boost local
economies) may divert the availability of soil and other natural
resources from use for food production. Ensuring the security of
the cannabis crop (particularly high THC content crops) in terms
of access to nonauthorized individuals and children is another
important regulatory consideration. Environmental impacts from
cannabis cultivation and processing, such as the emissions of
toxic air pollutants,65 or occupational health implications of
cannabis production, remain largely unexplored.40

3. Regulation of marketing and advertising
of cannabis
The marketing of cannabis products as medicinal (as opposed to
regulated CBM) is generally not regulated by agencies such as
the FDA or the European Medicines Agency using standards set
for pharmaceutical products, leading to reduced oversight of
health claims made for medicinal or recreational cannabis
products. A rapid growth of “expert cannabis clinics” is occurring,
where patients, often with complex medical comorbidities, are
treated predominantly with cannabis-based therapy, in lieu of a
comprehensive treatment approach.44 In addition, in contrast to
pharmacies where medications are dispensed by trained and
licensed professionals, most cannabis dispensaries are providing
drugs and medical advice by nonmedical personnel.36 These are
important considerations in the context of a worldwide expansion
of the for-profit cannabis industry. In the United States alone, the
sales of cannabis are projected to increase from $8.5 billion to
$75 billion by 2030.4 National and international cannabis brands
are emerging, with marketing campaigns on social media,
billboards, radio, and podcasts. Companies use slogans such
as “Welcome to the new normal,” and promote claims that
cannabinoids reduce anxiety, pain, and insomnia, improve skin,
“and much more,” without any adequate description of health
warnings or harms.4 When Canada legalized cannabis in 2018,
one of the fundamental principles in the Canadian Cannabis Act
was that cannabis should not be advertised or promoted in ways
that increase consumption.17 The U.S. states that have legalized
nonmedical cannabis vaguely prohibit advertising and
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promotions that appeal to children. However, a large survey
demonstrated that there is substantial exposure to cannabis
advertising among adolescents and adults both in Canada and in
the United States.63
Greater exposure to cannabis advertising is associated with
higher average use, intentions to use, and positive expectancies.21,57,63,79 Cannabis legalization and advertising has resulted
in perceptual shifts among population in North America, so that
50% of high school students across the United States now
endorse the belief that smoking cannabis regularly does not carry
great risk.51 The consequences of cannabis advertising mirror
those of alcohol and tobacco (ie, exposure to advertising
increases use, particularly in adolescents), but without regulations of cannabis advertising in place.1,32

4. Decriminalizing cannabis: harm vs harm reduction
The legal status of cannabis varies significantly around the globe.
Although some countries have legalized recreational use (eg,
Canada) or decriminalized personal use (eg, the Netherlands),
many countries allow cannabis for medicinal use only, or do not
endorse any legal status for cannabis.6,20,53 Under decriminalization, both production and sale remain illegal, but law
enforcement does not prosecute individuals for the possession
of small amounts of cannabis. Legalization, however, allows more
stringent regulation and taxation.
Diverse sources of evidence have identified associations
between administration of cannabinoids and development of
psychosis, motor vehicle accidents, respiratory problems,
cardiovascular problems, development of some cancers, and
low fetal birth weight.52 Conversely, several factors have driven
policymakers to increase access to cannabis. Cannabis legalization has been proposed as a solution to an overburdened lawenforcement system.55,56 For instance, the decrease in
cannabis-related arrests in Washington state after cannabis
legalization was shown to enable the police to reallocate
resources to other divisions; reduction of crime rates, including
rape, property crime, and theft, were observed,6 potentially
attributable to cannabis legalization. Although cannabis legalization may lead to reduction in overall cannabis-related arrests, the
effect of legalization on mitigating the substantial racial disparities
that exist in cannabis-related arrests is unclear.27,73
Leveraging some preclinical and clinical data suggesting
opioid-sparing effects of cannabinoids, legalization of cannabis
has been promoted as an attractive avenue to address the opioid
overdose crisis in the United States.6 A decriminalized or legalized
cannabis market also offers new sources of revenue for state
governments through taxation.13,45,56 However, some government employees and politicians involved in cannabis legislation
have come under increasing scrutiny with regards to nondisclosure of conflicts of interests with the cannabis industry.9,35
An important consideration in the debate of cannabis legalization
is the potential increase in cannabis sales on the black market, as a
result of price differentials between the legal (taxed) and illegal
markets. Diverting legally sourced cannabis for sale on the black
market negates some of the economic benefit to local governments. Recent estimates suggest that California’s illicit cannabis
market is worth approximately 4 times the size of its legal market.6
With emerging data on increased postlegalization societal
harms such as increased rates of psychiatric disorders, and
increased rates of hospital emergency department visits for
cannabis-related symptoms and toxicity presentations,6 the
benefits and harms of cannabis regulation should be carefully
considered and monitored.75
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5. How will legalizing unregulated recreational
cannabis affect medicinal cannabis use?
Laws governing recreational use affect medicinal cannabis use by
changing supply and demand, costs, taxation, purity, and
potency. Studies have shown that medicinal cannabis users are
different from those who use cannabis recreationally, with the
former reporting more medical problems, pain, and poor
function.62 This suggests that medicinal users of cannabis
consume cannabis for symptom management more so than for
recreation.
With the potency of cannabis increasing,26,58 there is concern
that recreational legalization will lead to medicinal cannabis users
bypassing medical advice on dosing, resulting in worse
outcomes. Nonregulated cannabinoid products with high THC
concentration (eg, 14% THC in “skunk” in the United Kingdom,
and up to 90% in “shatter” and “wax dabs” products in Colorado)
pose significant risk to consumers, as evidenced by increased
risk of psychosis in areas where such products become
available.23,48
Due to the availability of a wide variety of regulated and
unregulated cannabis products, and the high prevalence of their
consumption in patients who are prescribed medicinal cannabis, clinicians often struggle to discuss proper use of cannabinoids with patients.66 Beyond general education focusing on
harm reduction, clinicians often cannot access reliable information on the particular product a patient proposes to obtain
and use. Although many healthcare professionals support the
principle of using medicinal cannabis in certain patient
populations (particularly cancer patients and hospice patients),16 there is a widespread lack of self-perceived knowledge
surrounding all aspects of medicinal cannabis use among
clinicians.31 In contrast to pharmaceutical products, the information provided by cannabis manufacturers and their
representatives is not regulated, and thus, is highly variable.8,29
Organized and transparent regulatory policies, as well as
standardized prescribing and monitoring protocols, mirroring
those of pharmaceutical products, can greatly benefit the
prescription and monitoring of medicinal cannabis products to
improve patient safety.

Although some preclinical and clinical evidence suggest
opioid-sparing effects of cannabinoids, or analgesic synergy
between the 2 classes of drugs,18,41,76 one concern is that people
merely substitute one addictive substance with another.14 In
addition, despite pharmacological differences between opioids
and cannabinoids (notably overdose risk), there are nevertheless
concerning similarities between the economic forces and public
health messaging of perceived safety that fueled the opioid
epidemic in North America, and those that drive the global
expansion of medicinal cannabis use, without the appropriate
evidence of long-term efficacy and safety.28
The relationship between access to cannabis and opioid
prescription rates remains circumstantial, and the clinical
relevance of synergistic analgesia is currently conjectural, requiring further data at the population level.78 Moreover, the safety
of concurrent use of opioids and cannabis is unknown. There is
lack of consensus in policies at the hospital and physician level
regarding the importance of opioid tapering in patients with
concurrent use of cannabis,70 given the potential for drug
interactions and ongoing substance use.

7. Driving and operating machinery
Systematic reviews show consistent evidence that use of
cannabis impairs cognitive and psychomotor ability and impairs
driving skill.15 Effects are mainly acute but can last for 24 hours.
This is consistent with an association between acute cannabis
consumption and an approximate doubling in risk of motor
vehicle collision.2 Pilots accustomed to smoking cannabis and
trained in simulator tasks also have impaired function up to 24
hours after smoking. Despite these data, 1 in 5 teenagers has
reported driving under influence of cannabinoids,71 and chronic
pain patients treated with medical cannabis admit driving under
the influence of cannabis.7 Due to the risk of impaired attention,
memory, decision-making, and executive function with cannabis
use,19,61,80 there are also concerns about people in occupations
that require unimpaired cognitive abilities, such as clinicians in
acute care settings, and operators of heavy machinery.

8. Vulnerable populations
6. Changes in cannabis policy and opioid
use patterns
The legalization of cannabis in the midst of the “opioid epidemic”
in various jurisdictions created important research opportunities.
Studies reported that legalization of both cannabis use as well as
cannabis dispensaries (but not decriminalization of cannabis
alone) has been associated with subsequent reduction in rates of
opioid prescriptions, hospital admissions for opioid use disorder
and overdose (9%-28%), as well as in opioid deaths (16%24%).5,10,59,68,77 With a shift in U.S. opioid overdose deaths from
prescription opioids to heroin and synthetic opioids such as
fentanyl, however, the effects of cannabis legalization on opioid
overdose and deaths decreased, with some studies showing a
negative trend of more opioid overdoses.69 In one study of people
living with HIV and chronic pain, cannabis use was not associated
with lower odds of opioid initiation or higher odds of opioid
discontinuation.50 However, in another recent survey of opioid
substitution among people who have used cannabis, 41% of
opioid users reported a decrease or cessation of opioid use due
to cannabis use.43 A systematic review assessing the relationship
between cannabis use and decriminalization with opioid-related
outcomes provided mixed results.78

Certain populations may be more vulnerable to undesirable
effects of cannabinoids. Daily use of cannabis, particularly with
high THC content, is associated with about 50% risk of increased
depression, doubling the risk of psychosis or schizophrenia, and
a risk of developing cannabis dependence.40
There are substantial data showing psychological and cognitive vulnerabilities in adolescents with heavy or daily use of
cannabis,24,34,60 including higher levels of depression, risk of
psychosis, and poorer cognition and educational achievements.
Edible cannabis products have been associated with accidental poisoning in children,11,46,79 including a small mass-casualty
event caused by supplying of gummy candy containing THC at a
child’s birthday party.74 Trends to make cannabis-based edible
products more attractive to the consumer may increase
poisoning risk to children.
Cannabis use during pregnancy has been associated with
negative maternal outcomes such as preterm delivery and
preeclampsia, as well as neonatal outcomes such as anemia,
lower birth weight, and placement in neonatal intensive care.37,49
Despite these data, nearly 70% of cannabis dispensaries in
Colorado reported recommending cannabis products for the
treatment of nausea in the first trimester of pregnancy.25
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These risks must be carefully assessed and weighted against
possible benefits or widespread use of cannabinoids, including
for pain management.

9. Future steps in policy for reducing societal harms
As summarized in Table 1, major concerns remain over how
recreational laws will affect medicinal cannabis use, including
in people with pain. Changing supply and demand, taxation,
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potency, and marketing and advertising of cannabis are major
factors that affect public health. The presence of chemical and
microbial contaminants in cannabis products also pose
increased health risks, particularly in immunocompromised
patients. As the content of THC in cannabis is known to be
increasing in several countries, there is a concern that
legalization of recreational use will lead to medicinal users
bypassing medical advice on dosing, resulting in adverse
outcomes.

Table 1

Key societal issues and policy implications related to the use of cannabinoids, cannabis, and cannabis-based medicines in the
context of pain management.
Area of risk

Examples and implications

Area of need

Regulation of cannabis cultivation

Inconsistent and unregulated supply
Lack of standardization of allowable chemical and microbial
contaminants, posing particular risks to vulnerable populations
(eg, immunocompromised patients)
Labeling often not reflecting composition
Lack of regulated allowable THC content, resulting in extremely
high-potency products
Use of natural resources (eg, soil and water) and carbon footprint
of cannabis cultivation is not accounted for

Adoption of strict policies on cannabis
cultivation and quality control, to minimize
harm
Environmental implications need to be
considered and mitigated

Testing for cannabis and cannabinoid
safety and efficacy

Paucity of large, high-quality studies with cannabinoids in pain
The freedom of manufacturers to sell cannabis without a proof of
efficacy and safety minimizes their responsibility and motivation
to conduct large, rigorous studies

Use taxation of recreational and unregulated
medicinal cannabis, to fund large-scale
rigorous studies on efficacy and safety of
cannabis and cannabinoids in conditions such
as chronic pain

Marketing and advertising of cannabis
and cannabinoids

Cannabis and cannabinoid-containing products are widely
advertised on a variety of platforms, including social media
Little regulation exists over cannabis advertising; exposure to
advertising of potentially addictive substances increases use and
misuse, particularly among adolescents. Unregulated marketing
and advertising of cannabis has increased adolescent cannabis
use, and fueled the false perception that cannabis use is safe

Banning of advertising and promoting
cannabis, to mitigate societal harms
(particularly in children and adolescents)
Tight regulation of health claims made for
marketing
Mandatory demonstration of efficacy in high-quality
efficacy studies, to allow supporting health claims

Cannabis legalization and its effects on
medicinal cannabis use

Availability of nonmedicinal cannabis (potentially at lower price
and higher potency) will likely cause diversion to use cannabis
without careful medical supervision, increasing the likelihood of
adverse outcomes

Careful control of supply, quality, access, and
pricing of medicinal cannabis to prevent
adverse outcomes

Cannabis policy and opioid use

Possibility that opioid doses can be reduced by initiating
cannabis
Cannabis is being promoted as a solution for opioid overdose
crisis
The possible opioid-sparing effects of cannabinoids are unclear,
and the safety of opioid and cannabinoid combination is not
established

Careful experiments required to determine
opioid-sparing properties of cannabis
Safety of cannabinoid and opioid combinations
needs to be determined in rigorous trials

Driving and operating aircraft and
machinery

Cannabis impairs cognitive skills and reaction time, and doubles
the risk of motor vehicle collision
Consistent regulations on allowable use of cannabis (or blood
levels of THC) compatible with driving are lacking

Clear and consistent guidelines need to be set
regarding driving under cannabinoid influence,
as well as fast and reliable methods of testing
cannabis exposure

Cannabis legalization and its effects on
vulnerable populations

Daily or almost daily use of cannabis, particularly high-potency,
is linked with substantial increase in cognitive and psychiatric
problems, particularly among younger adults and adolescents,
and people with preexisting mental health problems
Immunosuppressed patients are at higher risk of toxicity from
potential chemical and microbial impurities and contaminants
found in cannabis
Edible cannabis products increase risk of accidental poisoning in
children
Cannabis use during pregnancy has been associated with
adverse maternal and neonatal outcomes

Introduce strict regulation for adult-only use of
cannabis (unless specifically prescribed by an
expert clinician for a childhood disorder such as
epilepsy)
Properly educate and implement programs for
minimizing exposure and use in high-risk
populations

THC, tetrahydrocannabinol.
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Adoption of strict governmental policies, at least those shown
to mitigate tobacco- and alcohol-related harms, would be
important.40 Regulation of production, sales, and allowable
THC contents of any product may increase cannabinoid safety.
Complete banning of advertising and promotion, together with
strong public education programs targeting vulnerable groups,
can help mitigate some of the societal harms.
Implementation and strict reinforcement of evidence-based
approaches for limiting driving under cannabinoid influence can
help reduce the amount of motor vehicle accidents. Even stricter
regulations should be implemented in the civil aviation and airline
industry.
Current data may be insufficient to make evidence-based
conclusions on each of these matters, but the speed at which
cannabinoid markets are growing outpaces the speed at
which high-quality data are generated. Measures to mitigate
individual and societal harms should therefore be implemented
rapidly.
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